Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2906 in Healthy Subjects and Obese Patients
NCT07280936Phase 1Active, not recruiting
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing SHR-2906 Injection Group with SHR-2906 Injection Placebo Group (2 arms). Primary endpoints: Incidence of adverse events at 113 days and Incidence of serious adverse events at 113 days. Started Jan 2026; status: active, not recruiting.
02
Drugs
SHR-2906
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07280936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07280936.